Prolonged suppressive L-thyroxin therapy longitudinal study of the L-T4 effect on bone density and bone metabolism markers an 71 patients;Traitement prolonge par L-thyroxine a visee suppressive etude longitudinale de l'influence de la LT4 sur la densite minerale osseuse et les marqueurs osseux metaboliques chez 71 patients

Presse Medicale

Volumn 28, Issue 7, 1999, Pages 323-329

  Rachedi, F ^a   Rohmer, V ^a   Six, P ^a   Duquenne, M ^a   Barbot, N Wion ^a   Minebois, A ^a   Bigorgne, J C ^a   Audran, M ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ESTROGEN; HYDROXYPROLINE; OSTEOCALCIN; PROGESTERONE; THYROXINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; BONE MINERALIZATION; DRUG EFFECT; ESTROGEN THERAPY; LONGITUDINAL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; THYROID TUMOR;

ADULT; BONE DENSITY; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROXINE;

EID: 0033585714     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19:35-63.
2. Trémollières F, Pouilles JM, Louvet JP, Ribot C. Perte osseuse transitoire au cours du traitement substitutif de l'hypothyroïdie - résultat d'une étude prospective sur deux ans. Rev Rhum (Paris) 1991; 58:859-75.
3. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressrve doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72:1184-8.
4. Kung AW, Lorentz T, Tam SC. Thyroxine suppressive therapy decreases bone mineral density in post menopausal women. Clin Endocrinol 1993; 39:535-40.
5. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259:3137-41.
6. Ross DS, Neer RM, Ridway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82:1167-70.
7. Taelman P, Kaufman JM, Janssens X, Vandercauter H, Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone. Clin Endocrinol 1990; 33:107-17.
8. Franklyn JA, Betteridge J, Daykin J et al. Long-term thyroxine therapy and bone mineral density. Lancet 1992; 340:9-13.
9. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A. Carefully monitoring levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994; 78:818-23.
10. Ribot C, Tremollieres F, Pouilles JM, Louvet JP. Bone mineral density and thyroid hormone therapy. Clin Endocrinol 1990; 33:143-53.
11. Fujiyama K, Kiriyama T, Ito M et al. Suppressive doses of Thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid 1995; 5:13-7.
12. Pioli G, Pedrazzoni M, Palummeri E et al. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol 1992; 126:238-42.
13. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113:265-9.
14. Minebois-Villégas A, Rohmer V, Rachédi F et al. Comparison of the analytical and clinical performances of three thyrotropin immunoassay kits. Ann Biol Clin 1995; 53:413-8.
15. Grant DJ, Mc Murdo MET, Mole PA, Paterson CR, Davies RR. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol 1993; 39:529-33.
16. Baran DT. Editorial: detrimental skeleton effects of thyrotropin suppressive doses of thyroxine: Fact or fantasy? J Clin Endocrinol Metab 1994; 78:816-7.
17. Diamond T, Vine J, Smart R, Butler P. Thyreotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994; 120:8-11.
18. Krolner B, Jorgensen JV, Nielsen SP. Spinal bone mineral content in myxoedema and thyreotoxicosis: effects of thyroid hormones and antithyroid treatment Clin Endocrinol 1983; 18:439-46.
19. Toh SH, Brown PH. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Min Res 1990; 5:463-7.
20. Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyreotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992; 75:1531-4.
21. Faber J, Galloe AM. Changes in bone density during prolonged subclinical hyperthyroidism due to L-thyroxine replacement treatment: a meta-analysis. Eur J Endocrinol 1994; 130:350-6.
22. Duncan WE, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid 1994; 4:183-90.
23. Harvey RD, McHardy KC, Reid W, Paterson F, Bewsher PD, Duncan A, Robins SP. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991; 72:1189-94.
24. Gam AN, Jensen GF, Hasselstrom K, Olsen M, Nielsen KS. Effects of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH. J Endocrinol Invest 1991; 14:451-5.
25. Franklyn JA, Betteridge J, Holder R, Daykin J, Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 1994; 41:425-32.
26. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrty in men chronically treated with suppressive doses of L-Thyroxine. J Bone Miner Res 1997; 12:72-7.
27. Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993; 3:17-23.
28. Coindre JM, David JP, Riviere L, Goussot JF, Roger P, De Mascarel A, Meunier PJ. Bone loss in hypothyroidism with hormone replacement-A histomorphometric study. Arch Intern Med 1966; 146:48-53.
29. Garnero P, Vassy V, Bertholin A, Riou P, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994; 78:955-9.
30. Frevert EU, Biester A, Müller MJ, Schmidt-Gayk H, Mühlen AV, Bradant G. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol 1994; 131:145-9.